Compare Incyte Corporation (INCY) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares Silver Trust — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while iShares Silver Trust trades at $54.78 (market cap $29.02B). The key difference: iShares Silver Trust is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and iShares Silver Trust for 89 Days on average.
| INCY | SLV | |
|---|---|---|
Market Cap | $22.85B | $29.02B |
Volume | 1,927,029 | 16,510,334 |
Sector | Health | — |
52-Week High | $129.93 | $105.57 |
52-Week Low | $83.80 | $42.40 |
Typical Hold Time | 33 Days | 89 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
SLV (iShares Silver Trust) trades at $53.45, down 0.69% with a bearish technical signal. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Assets surged to $13.41B while liabilities remain negligible at $5.98K. Technical indicators show oversold conditions with RSI at 26.02, though moving averages signal continued bearish pressure.
The outlook remains challenged by Federal Reserve policy uncertainty and rising Treasury yields pressuring precious metals. While oversold conditions may provide short-term bounce potential, the fundamental case lacks revenue generation. Investors face headwinds from dollar strength and hawkish Fed expectations, requiring careful risk management in this volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
